1-800-526-8630
1 of 4
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines help restore the functionality of cells & tissues and are applicable in numerous degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Researchers focus on developing technologies based on biologics, genes, somatic as well as stem cells. Stem cells are capable of proliferation and differentiation and hence, are critical in this field.
The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.
The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.
An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.
The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product Type
Cell Therapy
Gene Therapy
Tissue Engineering
Small Molecule & Biologic
By Material
Synthetic Material
Biodegradable Synthetic Polymer
Scaffold
Artificial Vascular Graft Material
Hydrogel Material
Biologically Derived Material
Collagen
Xenogeneic Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vectors
Genetically Manipulated Cell
Three-Dimensional Polymer Technology
Transgenic
Fibroblast
Neural Stem Cell
Gene-Activated Matrices
Pharmaceuticals
Small Molecule
Biologic
By Application
Cardiovascular
Oncology
Dermatology
Musculoskeletal
Wound Healing
Ophthalmology
Neurology
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Netherlands
Sweden
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Singapore
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Stryker Corporation
Zimmer Biomet Holdings, Inc.
Medtronic Plc.
Athersys, Inc.
U.S. Stem Cell, Inc. (Bioheart, Inc.)
Organogenesis, Inc. (Advanced Biohealing)
Integra Lifesciences Holdings Corporation
Acelity Holdings, Inc.
Isto Biologics (Isto Biologics Medical Systems, Inc.)
CryoLife, Inc.
The other players of the Regenerative Medicine market include (companies not profiled in the report):
Shimadzu Recursion Pharmaceuticals, Inc.
Baxter International, Inc.
DePuy Synthes
Siemens Healthineers
General Electric (GE) Company
Koninklijke Philips N.V.
Cloudmedx, Inc.
Bay Labs, Inc.
READ MORE
The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.
The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.
An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.
The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product Type
Cell Therapy
Gene Therapy
Tissue Engineering
Small Molecule & Biologic
By Material
Synthetic Material
Biodegradable Synthetic Polymer
Scaffold
Artificial Vascular Graft Material
Hydrogel Material
Biologically Derived Material
Collagen
Xenogeneic Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vectors
Genetically Manipulated Cell
Three-Dimensional Polymer Technology
Transgenic
Fibroblast
Neural Stem Cell
Gene-Activated Matrices
Pharmaceuticals
Small Molecule
Biologic
By Application
Cardiovascular
Oncology
Dermatology
Musculoskeletal
Wound Healing
Ophthalmology
Neurology
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Netherlands
Sweden
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Singapore
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Stryker Corporation
Zimmer Biomet Holdings, Inc.
Medtronic Plc.
Athersys, Inc.
U.S. Stem Cell, Inc. (Bioheart, Inc.)
Organogenesis, Inc. (Advanced Biohealing)
Integra Lifesciences Holdings Corporation
Acelity Holdings, Inc.
Isto Biologics (Isto Biologics Medical Systems, Inc.)
CryoLife, Inc.
The other players of the Regenerative Medicine market include (companies not profiled in the report):
Shimadzu Recursion Pharmaceuticals, Inc.
Baxter International, Inc.
DePuy Synthes
Siemens Healthineers
General Electric (GE) Company
Koninklijke Philips N.V.
Cloudmedx, Inc.
Bay Labs, Inc.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porters Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High adoption of stem cell technology
3.4.1.2. Emerging application of nanotechnology
3.4.1.3. Increasing prevalence of chronic diseases and trauma emergencies
3.4.1.4. Advancements in medical equipment technologies
3.4.2. Restraints
3.4.2.1. Ethical hurdles
3.4.2.2. Costly treatment associated with regenerative medicine
3.4.3. Opportunities
3.4.3.1. Lucrative opportunities of novel stem cell technologies
3.4.3.2. Increasing potential in emerging economies
3.4.3.3. Growing need of regenerative medicine in organ transplantation
CHAPTER 4: REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Cell Therapy
4.2.1. Key market trends
4.2.2. Key growth factors and growth opportunities
4.2.3. Market size and forecast
4.3. Gene Therapy
4.3.1. Key market trends
4.3.2. Key growth factors and growth opportunities
4.3.3. Market size and forecast
4.4. Tissue Engineering
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5. Small Molecules And Biologics
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5: REGENERATIVE MEDICINE MARKET, BY MATERIAL
5.1. Overview
5.1.1. Market size and forecast
5.2. Synthetic Materials
5.2.1. Market size and forecast, by region
5.2.2. Market size and forecast, by type
5.2.3. Biodegradable synthetic polymers
5.2.3.1. Market size and forecast
5.2.4. Scaffold
5.2.4.1. Market size and forecast
5.2.5. Artificial vascular graft materials
5.2.5.1. Market size and forecast
5.2.6. Hydrogel material
5.2.6.1. Market size and forecast
5.3. Biologically Derived Materials
5.3.1. Market size and forecast, by region
5.3.2. Market size and forecast, by type
5.3.3. Collagen
5.3.3.1. Market size and forecast
5.3.4. Xenogeneic material
5.3.4.1. Market size and forecast
5.4. Genetically Engineered Materials
5.4.1. Market size and forecast, by region
5.4.2. Market size and forecast, by type
5.4.3. Deoxyribonucleic acid transfection vectors
5.4.3.1. Market size and forecast
5.4.4. Genetically manipulated cells
5.4.4.1. Market size and forecast
5.4.5. Three-dimensional polymer technology
5.4.5.1. Market size and forecast
5.4.6. Transgenics
5.4.6.1. Market size and forecast
5.4.7. Fibroblasts
5.4.7.1. Market size and forecast
5.4.8. Neural stem cells
5.4.8.1. Market size and forecast
5.4.9. Gene-activated matrices
5.4.9.1. Market size and forecast
5.5. Pharmaceuticals
5.5.1. Market size and forecast, by region
5.5.2. Market size and forecast, by type
5.5.3. Small molecules
5.5.3.1. Market size and forecast
5.5.4. Biologics
5.5.4.1. Market size and forecast
CHAPTER 6: REGENERATIVE MEDICINE MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cardiovascular
6.2.1. Market size and forecast
6.3. Oncology
6.3.1. Market size and forecast
6.4. Dermatology
6.4.1. Market size and forecast
6.5. Musculoskeletal
6.5.1. Market size and forecast
6.6. Wound Healing
6.6.1. Market size and forecast
6.7. Ophthalmology
6.7.1. Market size and forecast
6.8. Neurology
6.8.1. Market size and forecast
6.9. Others
6.9.1. Market size and forecast
CHAPTER 7: REGENERATIVE MEDICINE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by material
7.2.5. Market size and forecast, by application
7.2.6. Market size and forecast, by country
7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast
7.3. Europe
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by product type
7.3.4. Market size and forecast, by material
7.3.5. Market size and forecast, by application
7.3.6. Market size and forecast, by country
7.3.6.1. Germany market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. UK market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast
7.4. Asia-Pacific
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by material
7.4.5. Market size and forecast, by application
7.4.6. Market size and forecast, by country
7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. Australia market size and forecast
7.4.6.4. India market size and forecast
7.4.6.5. South Korea market size and forecast
7.4.6.6. Taiwan market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast
7.5. Lamea
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by material
7.5.5. Market size and forecast, by application
7.5.6. Market size and forecast, by country
7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Venezuela market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast
CHAPTER 8: COMPANY PROFILES
8.1. Acelity Holdings, Inc. (Lifecell Corporation)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Key strategic moves and developments
8.2. Athersys, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. Cryolife, Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.4. Integra Lifesciences Corporation
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Key strategic moves and developments
8.6. Medtronic Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.7. Organogenesis Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Key strategic moves and developments
8.8. Stryker Corporation
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. U.S. Stem Cell, Inc. (Bioheart, Inc.)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. Zimmer Biomet Holdings, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porters Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. High adoption of stem cell technology
3.4.1.2. Emerging application of nanotechnology
3.4.1.3. Increasing prevalence of chronic diseases and trauma emergencies
3.4.1.4. Advancements in medical equipment technologies
3.4.2. Restraints
3.4.2.1. Ethical hurdles
3.4.2.2. Costly treatment associated with regenerative medicine
3.4.3. Opportunities
3.4.3.1. Lucrative opportunities of novel stem cell technologies
3.4.3.2. Increasing potential in emerging economies
3.4.3.3. Growing need of regenerative medicine in organ transplantation
CHAPTER 4: REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Cell Therapy
4.2.1. Key market trends
4.2.2. Key growth factors and growth opportunities
4.2.3. Market size and forecast
4.3. Gene Therapy
4.3.1. Key market trends
4.3.2. Key growth factors and growth opportunities
4.3.3. Market size and forecast
4.4. Tissue Engineering
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5. Small Molecules And Biologics
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5: REGENERATIVE MEDICINE MARKET, BY MATERIAL
5.1. Overview
5.1.1. Market size and forecast
5.2. Synthetic Materials
5.2.1. Market size and forecast, by region
5.2.2. Market size and forecast, by type
5.2.3. Biodegradable synthetic polymers
5.2.3.1. Market size and forecast
5.2.4. Scaffold
5.2.4.1. Market size and forecast
5.2.5. Artificial vascular graft materials
5.2.5.1. Market size and forecast
5.2.6. Hydrogel material
5.2.6.1. Market size and forecast
5.3. Biologically Derived Materials
5.3.1. Market size and forecast, by region
5.3.2. Market size and forecast, by type
5.3.3. Collagen
5.3.3.1. Market size and forecast
5.3.4. Xenogeneic material
5.3.4.1. Market size and forecast
5.4. Genetically Engineered Materials
5.4.1. Market size and forecast, by region
5.4.2. Market size and forecast, by type
5.4.3. Deoxyribonucleic acid transfection vectors
5.4.3.1. Market size and forecast
5.4.4. Genetically manipulated cells
5.4.4.1. Market size and forecast
5.4.5. Three-dimensional polymer technology
5.4.5.1. Market size and forecast
5.4.6. Transgenics
5.4.6.1. Market size and forecast
5.4.7. Fibroblasts
5.4.7.1. Market size and forecast
5.4.8. Neural stem cells
5.4.8.1. Market size and forecast
5.4.9. Gene-activated matrices
5.4.9.1. Market size and forecast
5.5. Pharmaceuticals
5.5.1. Market size and forecast, by region
5.5.2. Market size and forecast, by type
5.5.3. Small molecules
5.5.3.1. Market size and forecast
5.5.4. Biologics
5.5.4.1. Market size and forecast
CHAPTER 6: REGENERATIVE MEDICINE MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cardiovascular
6.2.1. Market size and forecast
6.3. Oncology
6.3.1. Market size and forecast
6.4. Dermatology
6.4.1. Market size and forecast
6.5. Musculoskeletal
6.5.1. Market size and forecast
6.6. Wound Healing
6.6.1. Market size and forecast
6.7. Ophthalmology
6.7.1. Market size and forecast
6.8. Neurology
6.8.1. Market size and forecast
6.9. Others
6.9.1. Market size and forecast
CHAPTER 7: REGENERATIVE MEDICINE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by material
7.2.5. Market size and forecast, by application
7.2.6. Market size and forecast, by country
7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast
7.3. Europe
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by product type
7.3.4. Market size and forecast, by material
7.3.5. Market size and forecast, by application
7.3.6. Market size and forecast, by country
7.3.6.1. Germany market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. UK market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast
7.4. Asia-Pacific
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by material
7.4.5. Market size and forecast, by application
7.4.6. Market size and forecast, by country
7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. Australia market size and forecast
7.4.6.4. India market size and forecast
7.4.6.5. South Korea market size and forecast
7.4.6.6. Taiwan market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast
7.5. Lamea
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by material
7.5.5. Market size and forecast, by application
7.5.6. Market size and forecast, by country
7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Venezuela market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast
CHAPTER 8: COMPANY PROFILES
8.1. Acelity Holdings, Inc. (Lifecell Corporation)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Key strategic moves and developments
8.2. Athersys, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. Cryolife, Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.4. Integra Lifesciences Corporation
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Key strategic moves and developments
8.6. Medtronic Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.7. Organogenesis Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Key strategic moves and developments
8.8. Stryker Corporation
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. U.S. Stem Cell, Inc. (Bioheart, Inc.)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. Zimmer Biomet Holdings, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
According to a new report titled, Regenerative Medicine Market by Product Type, Material, and Application: Global Opportunity Analysis and Industry Forecast, 2017-2023" the global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. North America is the highest contributor in the regenerative medicine market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.
Currently, majority of the available treatments for degenerative or life-threatening diseases do not provide a cure or are palliative; however, regenerative medicines have the capability to replace or regenerate the tissues and organs that are injured or diseased. Moreover, the utilization of nanomaterials in wound care, drug delivery, and immunomodulation create growth opportunities for the regenerative medicines market.
The major factors boosting the market growth include technological advancements in tissue and organ regeneration, increasing prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market. However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are the key factors affecting the market growth. Furthermore, advancements in stem cell technology and achieving core competency in the emerging economies are expected to fuel the market growth. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which would aid the expansion of the global market.
The cell therapy segment accounted for a significant share of about three-fifth the overall regenerative medicine market in 2016 due to the widespread adoption of cell therapy for treatment of several diseases such as musculoskeletal, cardiovascular, oncology, wound healing, and others. Small molecules and biologics has emerged as the fastest growing segment during the forecast period as these biologics are classic active substances delivering better overall economic return. These molecules have revolutionized the treatment of specific diseases such as musculoskeletal diseases, cancer, rheumatoid arthritis, and non-healing wounds.
Musculoskeletal and wound healing segment accounted for about three-fifth share of the application market in 2016. Cell therapies are used in the treatment of musculoskeletal diseases such as bone tissue replacement, cartilage, tendon, and ligament repair and replacement. In addition, osteoporosis is one of the most prevalent diseases that require tissue engineering therapies. More than 75 million people suffer from osteoporosis in Europe, the U.S., and Japan every year, which boosts the demand for regenerative medicines.
Geographically, North America accounted for majority of the share of the overall regenerative medicine market in 2016, and is expected to maintain this trend during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.
Key findings of the Regenerative Medicine Market:
Small molecules and biologics segment is projected to grow at the highest rate among the product type segment during the analysis period.
North America dominated global regenerative medicine market in 2016, and is projected to continue its dominance in future.
China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.
Biologically derived materials segment was the largest contributor among the material segments in 2016.
The synthetic materials segment generated the highest revenue, and is expected to continue its dominance in future.
The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc. Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.
Currently, majority of the available treatments for degenerative or life-threatening diseases do not provide a cure or are palliative; however, regenerative medicines have the capability to replace or regenerate the tissues and organs that are injured or diseased. Moreover, the utilization of nanomaterials in wound care, drug delivery, and immunomodulation create growth opportunities for the regenerative medicines market.
The major factors boosting the market growth include technological advancements in tissue and organ regeneration, increasing prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market. However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are the key factors affecting the market growth. Furthermore, advancements in stem cell technology and achieving core competency in the emerging economies are expected to fuel the market growth. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which would aid the expansion of the global market.
The cell therapy segment accounted for a significant share of about three-fifth the overall regenerative medicine market in 2016 due to the widespread adoption of cell therapy for treatment of several diseases such as musculoskeletal, cardiovascular, oncology, wound healing, and others. Small molecules and biologics has emerged as the fastest growing segment during the forecast period as these biologics are classic active substances delivering better overall economic return. These molecules have revolutionized the treatment of specific diseases such as musculoskeletal diseases, cancer, rheumatoid arthritis, and non-healing wounds.
Musculoskeletal and wound healing segment accounted for about three-fifth share of the application market in 2016. Cell therapies are used in the treatment of musculoskeletal diseases such as bone tissue replacement, cartilage, tendon, and ligament repair and replacement. In addition, osteoporosis is one of the most prevalent diseases that require tissue engineering therapies. More than 75 million people suffer from osteoporosis in Europe, the U.S., and Japan every year, which boosts the demand for regenerative medicines.
Geographically, North America accounted for majority of the share of the overall regenerative medicine market in 2016, and is expected to maintain this trend during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.
Key findings of the Regenerative Medicine Market:
Small molecules and biologics segment is projected to grow at the highest rate among the product type segment during the analysis period.
North America dominated global regenerative medicine market in 2016, and is projected to continue its dominance in future.
China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.
Biologically derived materials segment was the largest contributor among the material segments in 2016.
The synthetic materials segment generated the highest revenue, and is expected to continue its dominance in future.
The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc. Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
